Unknown

Dataset Information

0

Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma.


ABSTRACT: There are currently several options for tyrosine kinase inhibitor as a systemic therapy for metastatic renal cell carcinoma (mRCC). The successful control of adverse events caused by such drugs, along with eliciting long-term maximum effect, are the major issues with respect to the treatment strategy for mRCC. We herein report the clinical course of mRCC, in which erythema multiforme major was observed on the 13th day of the first course of sunitinib, but the symptoms improved after the immediate withdrawal of sunitinib, as well as the administration of topical steroids and oral antihistamines alone.

SUBMITTER: Watanabe D 

PROVIDER: S-EPMC6558298 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma.

Watanabe Daisuke D   Yamashita Akemi A   Minowa Tadaaki T   Miura Kunihisa K   Mizushima Akio A  

Urology case reports 20190604


There are currently several options for tyrosine kinase inhibitor as a systemic therapy for metastatic renal cell carcinoma (mRCC). The successful control of adverse events caused by such drugs, along with eliciting long-term maximum effect, are the major issues with respect to the treatment strategy for mRCC. We herein report the clinical course of mRCC, in which erythema multiforme major was observed on the 13th day of the first course of sunitinib, but the symptoms improved after the immediat  ...[more]

Similar Datasets

| S-EPMC5516884 | biostudies-literature
| S-EPMC5117167 | biostudies-literature
| S-EPMC5032140 | biostudies-literature
| S-EPMC3441135 | biostudies-literature
| S-EPMC3228204 | biostudies-literature
| S-EPMC5434501 | biostudies-literature
| S-EPMC3219862 | biostudies-literature
| S-EPMC3950861 | biostudies-literature
| S-EPMC5978253 | biostudies-literature
| S-EPMC5345511 | biostudies-literature